• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A head-to-head comparison of risankizumab and ixekizumab for genital psoriasis: a real-life, 24-week, prospective study.

作者信息

Sotiriou E, Bakirtzi K, Papadimitriou I, Tsentemeidou A, Eftychidou P, Eleftheriadis V, Lallas A, Ioannides D, Vakirlis E

机构信息

First Department of Dermatology and Venereology, Aristotle University, Thessaloniki, Greece.

出版信息

J Eur Acad Dermatol Venereol. 2022 May;36(5):e359-e361. doi: 10.1111/jdv.17880. Epub 2021 Dec 31.

DOI:10.1111/jdv.17880
PMID:34923693
Abstract
摘要

相似文献

1
A head-to-head comparison of risankizumab and ixekizumab for genital psoriasis: a real-life, 24-week, prospective study.司库奇尤单抗与依奇珠单抗治疗生殖器银屑病的头对头比较：一项为期24周的真实世界前瞻性研究。
J Eur Acad Dermatol Venereol. 2022 May;36(5):e359-e361. doi: 10.1111/jdv.17880. Epub 2021 Dec 31.
2
Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison.古塞库单抗和司库奇尤单抗治疗银屑病：44周间接真实世界比较
J Am Acad Dermatol. 2021 Oct;85(4):1028-1030. doi: 10.1016/j.jaad.2021.01.025. Epub 2021 Mar 21.
3
Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate-to-severe genital psoriasis.司库奇尤单抗可改善中重度生殖器银屑病患者的继发性皮损体征、疼痛及性健康状况。
J Eur Acad Dermatol Venereol. 2020 Jun;34(6):1257-1262. doi: 10.1111/jdv.16181. Epub 2020 Feb 5.
4
Risankizumab for the treatment of genital psoriasis: A 1-year, real-world experience.瑞莎珠单抗治疗生殖器银屑病：1年的真实世界经验。
J Eur Acad Dermatol Venereol. 2024 Mar;38(3):e256-e258. doi: 10.1111/jdv.19562. Epub 2023 Oct 17.
5
Ixekizumab Improved Patient-Reported Genital Psoriasis Symptoms and Impact of Symptoms on Sexual Activity vs Placebo in a Randomized, Double-Blind Study.依奇珠单抗改善患者报告的生殖器银屑病症状，与安慰剂相比，在一项随机、双盲研究中改善症状对性行为的影响。
J Sex Med. 2018 Nov;15(11):1645-1652. doi: 10.1016/j.jsxm.2018.09.004.
6
Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.生物制剂治疗中重度斑块状银屑病患者的短期疗效：系统评价和网络荟萃分析。
J Dermatol Sci. 2020 Jul;99(1):53-61. doi: 10.1016/j.jdermsci.2020.06.003. Epub 2020 Jun 18.
7
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.中度至重度斑块状银屑病患者中，ixekizumab与guselkumab的头对头比较：一项随机双盲试验的12周疗效、安全性及反应速度
Br J Dermatol. 2020 Jun;182(6):1348-1358. doi: 10.1111/bjd.18851. Epub 2020 Jan 15.
8
Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis.在一项随机、双盲、安慰剂对照的 IIIb 期研究中，评估 ixekizumab 在中重度生殖器银屑病患者中的疗效和安全性。
Br J Dermatol. 2018 Oct;179(4):844-852. doi: 10.1111/bjd.16736. Epub 2018 Jul 22.
9
Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.短期疗效和安全性的白介素-17、白介素-12/23 和白介素-23 抑制剂布罗达单抗、司库奇尤单抗、依奇珠单抗、乌司奴单抗、古塞库单抗、替西珠单抗和瑞莎珠单抗治疗中度至重度斑块状银屑病：随机对照试验的系统评价和网络荟萃分析。
J Immunol Res. 2019 Sep 10;2019:2546161. doi: 10.1155/2019/2546161. eCollection 2019.
10
Exclusively genital psoriasis successfully treated with Risankizumab.仅累及生殖器的银屑病经司库奇尤单抗治疗成功。
Dermatol Ther. 2022 Aug;35(8):e15591. doi: 10.1111/dth.15591. Epub 2022 Jun 6.

引用本文的文献

1
Bimekizumab for the Treatment of Plaque Psoriasis with Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis).比美吉珠单抗治疗累及生殖器的斑块状银屑病：一项为期16周的多中心真实世界研究——IL PSO（意大利银屑病概况）
Dermatol Pract Concept. 2024 Apr 1;14(2):e2024052. doi: 10.5826/dpc.1402a52.
2
Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO).生物制剂对中度至重度银屑病及特殊部位受累患者的比较疗效：健康结局银屑病观察研究（PSoHO）第12周结果
Front Med (Lausanne). 2023 Jun 29;10:1185523. doi: 10.3389/fmed.2023.1185523. eCollection 2023.
3
The PI3K-Akt-mTOR and Associated Signaling Pathways as Molecular Drivers of Immune-Mediated Inflammatory Skin Diseases: Update on Therapeutic Strategy Using Natural and Synthetic Compounds.PI3K-Akt-mTOR 及相关信号通路作为免疫介导性炎症性皮肤病的分子驱动因素：天然和合成化合物治疗策略的最新进展。
Cells. 2023 Jun 20;12(12):1671. doi: 10.3390/cells12121671.
4
Psoriasis and sexuality: Patients express their feelings.银屑病与性：患者表达自身感受。
Skin Health Dis. 2022 Dec 28;3(3):e199. doi: 10.1002/ski2.199. eCollection 2023 Jun.
5
Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study.司库奇尤单抗治疗中度至重度银屑病的长期疗效和安全性：一项为期2年的真实世界回顾性研究
J Clin Med. 2023 Apr 30;12(9):3233. doi: 10.3390/jcm12093233.
6
Risankizumab for the Treatment of Moderate to Severe Psoriasis: Impact on Health-Related Quality of Life and Psychological Wellbeing.司库奇尤单抗治疗中度至重度银屑病：对健康相关生活质量和心理健康的影响。
Clin Cosmet Investig Dermatol. 2023 Jan 25;16:221-229. doi: 10.2147/CCID.S296544. eCollection 2023.
7
Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines.根据西班牙银屑病指南的治疗目标，评估司库奇尤单抗在西班牙安达卢西亚实际临床实践中的中期（52周）疗效、安全性及生存率
Life (Basel). 2022 Nov 14;12(11):1883. doi: 10.3390/life12111883.
8
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence.古塞库单抗、司库奇尤单抗和替拉珠单抗治疗银屑病的真实世界证据综述
Clin Cosmet Investig Dermatol. 2022 Aug 16;15:1649-1658. doi: 10.2147/CCID.S364640. eCollection 2022.
9
Curbing COVID-19 Vaccine Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the Vaccine Adverse Event Reporting System (VAERS) Database.从皮肤科角度抑制 COVID-19 疫苗犹豫：疫苗不良事件报告系统 (VAERS) 数据库中皮肤反应的分析。
Am J Clin Dermatol. 2022 Sep;23(5):729-737. doi: 10.1007/s40257-022-00715-x. Epub 2022 Aug 5.
10
[Erythrodermic psoriasis after COVID-19].新型冠状病毒肺炎后红皮病型银屑病
Hautarzt. 2022 Feb;73(2):156-159. doi: 10.1007/s00105-021-04931-0. Epub 2021 Dec 14.